@article{TLCR21273,
author = {Federico Rotolo and Chang-Qi Zhu and Elisabeth Brambilla and Stephen L. Graziano and Ken Olaussen and Thierry Le-Chevalier and Jean-Pierre Pignon and Robert Kratzke and Jean-Charles Soria and Frances A. Shepherd and Lesley Seymour and Stefan Michiels and Ming-Sound Tsao and on behalf of the LACE-Bio Consortium},
title = {Genome-wide copy number analyses of samples from LACE-Bio project identify novel prognostic and predictive markers in early stage non-small cell lung cancer},
journal = {Translational Lung Cancer Research},
volume = {7},
number = {3},
year = {2018},
keywords = {},
abstract = {Background: Adjuvant chemotherapy (ACT) provides modest benefit in resected non-small cell lung cancer (NSCLC) patients. Genome-wide studies have identified gene copy number aberrations (CNA), but their prognostic implication is unknown.
Methods: DNA from 1,013 FFPE tumor samples from three pivotal multicenter randomized trials (ACT vs. control) in the LACE-Bio consortium (median follow-up: 5.2 years) was successfully extracted, profiled using a molecular inversion probe SNP assay, normalized relative to a pool of normal tissues and segmented. Minimally recurrent regions were identified. P values were adjusted to control the false discovery rate (Q values).
Results: A total of 976 samples successfully profiled, 414 (42%) adenocarcinoma (ADC), 430 (44%) squamous cell carcinoma (SCC) and 132 (14%) other NSCLC; 710 (73%) males. We identified 431 recurrent regions, with on average 51 gains and 43 losses; 253 regions (59%) were ≤3 Mb. Most frequent gains (up to 48%) were on chr1, 3q, 5p, 6p, 8q, 22q; most frequent losses (up to 40%) on chr3p, 8p, 9p. CNA frequency of 195 regions was significantly different (Q≤0.05) between ADC and SCC. Fourteen regions (7p11–12, 9p21, 18q12, and 19p11–13) were associated with disease-free survival (DFS) (univariate P≤0.005, Q},
issn = {2226-4477}, url = {https://tlcr.amegroups.org/article/view/21273}
}